Solubilizing Vehicles for Oral Formulation Development

Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VI)


This chapter focuses on solubilizing excipients in oral formulations with selected examples of commercially available over-the-counter and prescription human pharmaceutical products. The intent is to educate the reader on the need for and the chemical contents of solubilized oral formulations, and to act as a practical guide in assisting the development scientist in choosing a solubilizing vehicle for oral administration. The formulation philosophy is to minimize the excipients and the suggested development approach is from “simple to complex” (i.e., keep the formulation as simple as possible). This chapter is organized in four sections. The first section is an introduction with basic concepts. The second section addresses solubilizing excipients and mixtures of excipients. The third section deals with liquid-filled capsules. The fourth section focuses on oral solutions. The last three sections are further divided into water-soluble vehicles and lipidcontaining vehicles.


Propylene Glycol Solid Dispersion Oral Solution Ascorbyl Palmitate Testosterone Undecanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bekerman T, Golenser J, and Domb A. Cyclosporin Nanoparticulate Lipospheres for Oral Administration. J Pharm Sci 2004; 93: 1264–1270.PubMedCrossRefGoogle Scholar
  2. Bummer PM. Physical Chemical Considerations of Lipid-Based Oral Drug Delivery-Solid Lipid Nanoparticles. Crit Reviews in Ther Drug Carrier Sys 2004; 21: 1–19.CrossRefGoogle Scholar
  3. Cawley D and Stern MH. Water-Soluble Tocopherol Derivatives. US Patent 1954: 2,680,749.Google Scholar
  4. Constantinides PP, Han J, and Davis SS. Advances in the Use of Tocols as Drug Delivery Vehicles. Pharm Res 2006; 23: 243–255.PubMedCrossRefGoogle Scholar
  5. Constantinides PP, Tustian A, and Kessler DR. Toco Emulsions for Drug Solubilization and Parenteral Delivery. Adv Drug Del Rev 2004; 56: 1243–1255.CrossRefGoogle Scholar
  6. Dannenfelser R-M, He H, Joshi Y, Bateman S, and Serajuddin ATM. Development of Clinical Dosage Forms for a Poorly Water-Soluble Drug I: Applications of Polyethylene Glycol-Polysorbate 80 Solid Dispersion Carrier System. J Pharm Sci 2004; 93: 1165–1175. Internet websites accessed February 2007: 1) 2) 3) 4) 5) 6) for the European Union: http: 7) for Sweden: 8) for New Zealand: 9) for South Africa: 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) 21) 22) 23) 24) Scholar
  7. Irie T and Uekama K. Pharmaceutical Applications of Cyclodextrins. III. Toxicology Issues and Safety Evaluation. J Pharm Sci 1997; 86: 147–162.PubMedCrossRefGoogle Scholar
  8. Lamarre D. An NS3 Protease Inhibitor with Antiviral Effects in Humans Infected with Hepatitis C Virus. Nature 2003; 426: 186–189.PubMedCrossRefGoogle Scholar
  9. Liu R., Water-Insoluble Drug Formulation, Interpharm Press, Denver, Colorado, 2000.Google Scholar
  10. Loftsson TL and Brewster ME. Pharmaceutical Applications of Cyclodextrins. I. Drug Solubilization and Stabilization. J Pharm Sci 1996; 85: 1017–1024.PubMedCrossRefGoogle Scholar
  11. Nerurkar J, Beach JW, Park MO, and Jun HW. Solubility of (±)-Ibuprofen and the S (+)-Ibuprofen in the Presence of Cosolvents and Cyclodextrins. Pharm Dev and Tech 2005; 10:413–421.Google Scholar
  12. Peeters J, Neeskens P, Tollenaere JP, Remoortere PV, and Brewster ME. Characterization of the Interaction of 2-Hydroxypropyl-ß-Cyclodextrin with Itraconazole at pH 2, 4, and 7. J Pharm Sci 2002; 91: 1414–1422.PubMedCrossRefGoogle Scholar
  13. Physician's Desk Reference, 60th ed., Thomson Healthcare, Inc., Montvale, NJ, 2006.Google Scholar
  14. Powell MF, Nguyen T, and Baloian L. Compendium of Excipients for Parenteral Formulations. J Parent Sci Technol 1998; 52: 238–411.Google Scholar
  15. Schulze JDR, Waddington WA, Ell PJE, Parsons GE, Coffin MD, and Basit AW. Concentration-Dependent Effects of Polyethylene Glycol 400 on Gastrointestinal Transit and Drug Absorption. Pharm Res 2003; 20: 1984–1988.PubMedCrossRefGoogle Scholar
  16. Serajuddin ATM. Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises, Subsequent Problems, and Recent Breakthroughs. J Pharm Sci 1999; 88: 1058–1066.PubMedCrossRefGoogle Scholar
  17. Strickley RG. Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part I. J Parent Sci Technol 1999; 53: 324–349.Google Scholar
  18. Strickley RG. Solubilizing Excipients in Oral and Injectable Formulations. Pharm Res 2004; 21: 201–230.PubMedCrossRefGoogle Scholar
  19. Stuchlik M and Zak, S. Lipid-Based Vehicle for Oral Delivery. Biomed Papers 2001; 145: 17–26.Google Scholar
  20. Sweetana S and Akers MJ. Solubility Principles and Practices for Parenteral Dosage Form Development. J Parent Sci Technol 1996; 50: 330–342.Google Scholar
  21. Tenjarla S. Microemulsions: An Overview and Pharmaceutical Applications. Crit Reviews in Ther Drug Carrier Sys 1999; 16: 461–521.Google Scholar
  22. Wang Y-C J and Kowal RR. Review of Excipients and pH's for Parenteral Products Used in the United States. J Parent Sci Technol 1980; 34: 452–462.Google Scholar
  23. Won D-H, Kim M-S, Lee S, Park J-S, and Hwang S-J. Improved Physicochemical Characteristics of Felodipine Solid Dispersion Particles by Supercritical Anti-Solvent Precipitation Process. Intl J Pharm 2005; 301: 199–208.CrossRefGoogle Scholar
  24. Wu SH-W and Hopkins WK. Characteristics of D-α-Tocopheryl PEG 1000 Succinate for Applications as an Absorption Enhancer in Drug Delivery SystemsPharm Tech 1999; 23: 52–68.Google Scholar
  25. York P, Kompella UB, and Shekunov BY. Supercritical Fluid Technology for Drug Product Development. Marcel Dekker, Inc., New York, NY, 2004.Google Scholar
  26. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, and Coffin M. Vitamin-E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing its Solubility and Permeability. Pharm Res 1999; 16: 1812–1817.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

    • 1
    • 1
  1. 1.Formulation & Process Development, Gilead SciencesFoster City

Personalised recommendations